A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma

PURPOSE: This phase I study investigated the maximum-tolerated dose (MTD), safety, pharmacodynamics, immunological correlatives, and anti-tumor activity of CP-870,893, an agonist CD40 antibody, when administered in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcino...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Beatty, Gregory L., Torigian, Drew A., Chiorean, E. Gabriela, Saboury, Babak, Brothers, Alex, Alavi, Abass, Troxel, Andrea B., Sun, Weijing, Teitelbaum, Ursina R., Vonderheide, Robert H., O’Dwyer, Peter J.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3834036/
https://ncbi.nlm.nih.gov/pubmed/23983255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-1320
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars